The article reports on the U.S. Food and Drug Administration's (FDA's) approval of a 3D-printed quick-dissolving version of levetiracetam for young child with epilepsy. It is stated that the approval is the latest evidence that 3D printing is taking off in medicine as a way to overcome patient-specific challenges.